Quest Diagnostics

WuXi PharmaTech

Johnson & Johnson Innovation inks 17 collaborations

Friday, June 12, 2015 12:02 PM

Johnson & Johnson Innovation has announced 17 new collaborations with research institutions and healthcare companies, bringing the total number of collaborations formed since the 2013 launch of Johnson & Johnson Innovation to more than 200. Johnson & Johnson Innovation seeks to identify and advance scientific innovation across the Johnson & Johnson segments of Pharmaceutical, Medical Devices and Consumer businesses.

More... »


WuXi AppTec partners with Fudan University, CICGD

Monday, June 8, 2015 01:18 PM

Global CRO WuXi AppTec has partnered with China’s Fudan University to bring WuXi NextCODE's population human genomics database system and integrated research and clinical solutions to the Fudan-led Collaborative Innovation Center of Genetics and Development (CICGD) as an enterprise partner. The partnership will empower CICGD scientists to perform gene sequencing and bioinformatics analysis with unparalleled speed and precision, thereby accelerating research, clinical diagnosis and treatment of rare inherited diseases and malignant tumors.

More... »


Fosun Pharma, HOPU Investments, CEL Healthcare Fund, WuXi PharmaTech to acquire Ambrx

Friday, May 22, 2015 01:50 PM

A consortium—consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU InvestmentsChina Everbright’s Healthcare Fund and WuXi PharmaTech—has signed a merger agreement to acquire Ambrx. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions.

More... »

WuXi PharmaTech forms special committee to evaluate non-binding proposal

Friday, May 15, 2015 02:22 PM

Global CRO WuXi PharmaTech has announced that, in response to a preliminary non-binding proposal letter, dated April 29, received by the company's board of directors from Dr. Ge Li, founder, chairman and CEO of the company, and Ally Bridge Group Capital Partners to acquire the company in a "going private" transaction, the board has formed a special committee of independent directors consisting of Xuesong (Jeff) Leng, William R. Keller and Walter T. Kwauk to evaluate the proposed transaction.  

More... »

WuXi NextCODE Genomics, DNAnexus partner

Friday, April 24, 2015 01:27 PM

WuXi NextCODE Genomics, a subsidiary of WuXi PharmaTech, an open-access R&D capability and technology platform company, and DNAnexus, an cloud-based genome informatics and data management company, have formed a strategic alliance that aims to accelerate the use of genomics to benefit patients worldwide.

More... »

WuXi PharmaTech acquires NextCODE Health

Friday, January 9, 2015 01:58 PM

WuXi PharmaTech, an open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries with operations in China and the U.S., has acquired NextCODE Health, a genomic analysis and bioinformatics company with operations in the U.S. and Iceland, for $65 million in cash.

More... »

WuXi opening offices in Boston and San Francisco

Monday, December 22, 2014 02:13 PM

CRO WuXi PharmaTech (Cayman), an open-access R&D capability and technology platform company with operations in China and the U.S., will open offices in Boston and San Francisco in early 2015.

More... »

WuXi AppTec launches enhanced genomics services for Chinese researchers

Monday, December 1, 2014 12:39 PM

WuXi PharmaTech, an open-access R&D capability and technology platform company serving the pharma, biotech and medical device industries with operations in China and the U.S., has announced an enhancement to its genomics services. The WuXi Genome Center will provide Chinese researchers who use its gene sequencing services with access to the integrated sequence analysis capabilities of NextCODE Health, a bioinformatics company based in Cambridge, Mass.

More... »

WuXi PharmaTech acquires XenoBiotic Laboratories

Wednesday, October 1, 2014 01:11 PM

CRO WuXi PharmaTech, with operations in China and the U.S., has acquired XenoBiotic Laboratories (XBL), a CRO with facilities in New Jersey and China. Financial terms have not been disclosed.

More... »

FDA approves WuXi’s manufacture of ibalizumab in China for use under a U.S. IND

Wednesday, May 7, 2014 01:32 PM

The FDA has approved the first batch of the ibalizumab (TMB-355) drug substance and sterile drug product, manufactured at WuXi PharmaTech's biologics facilities and developed by TaiMed Biologics for the treatment of HIV/AIDS infection. 

More... »


CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs